SIRO Clinpharm, a clinical research organisation headquartered in Mumbai, India has appointed Gopakumar Menon as chief executive to build and enhance the firm’s biopharma service offering, across the US, Europe and Asia.
Menon has been working in the pharmaceutical industry for the more than 12 years in various capacities, from discovery to sales and marketing.
Prior to joining SIRO Clinpharm he worked for Boston, US-based Sciformix. He has had significant experience working with Fortune 500 companies such as Cognizant and Satyam, as well as with venture funded start-up organisations.
SIRO Clinpharm has offices in India, Malaysia, US, Israel Germany, Romania, Estonia, Greece, Czech Republic and Spain.
SIRO Clinpharm appoints chief executive
Takes responsibility for expanding business across the US, Europe and Asia
You may also like
Drug Delivery
Bio-Sourcing and Zerion Pharma secure Eurostars funding to develop HER2 oral monoclonal antibody
The pair have been awarded a €1.3m Eurostars grant to develop an oral formulation of the anti-HER2 monoclonal antibody trastuzumab for breast cancer, combining Bio-Sourcing’s BioMilk platform with Zerion’s Dispersome technology to advance the candidate through preclinical development
Research & Development
FairJourney Bio launches cryo-EM services to support antibody discovery and biologics design
The new offering at the company's San Diego laboratories provides high-resolution structural insights to accelerate antibody discovery, selection and optimisation across the biologics R&D pipeline
Research & Development
Studies on HIV and TB reveal tradeoffs for both viruses and immune system in race to survive
Research teams have identified mechanisms by which HIV can evade lenacapavir, at the cost of the virus's reproduction and how the immune system can use bacteria to protect against infection — until TB evolved to take advantage
Research & Development
Enara Bio expands Boehringer Ingelheim partnership as DARKFOX programme moves toward the clinic
Enara Bio has entered 2026 with renewed momentum after Boehringer Ingelheim licensed additional Dark Antigen targets under their oncology collaboration. The company is also continuing to expand its EDAPT discovery platform
Research & Development
Early stage clinical trials highlight the convergence of novel therapeutics and enabling technologies
Early stage clinical development is increasingly being shaped by advances in drug discovery and the technologies and manufacturing strategies that enable the safe, precise and scalable delivery of new therapies